TAVR After Endocarditis? Contraindication or Last Resort

Transcatheter aortic valve replacement (TAVR) can be an alternative for aortic valves with endocarditis successfully treated with antibiotics, which no longer are severe valve lesions.

TAVI post endocarditis

At one year, the risk of endocarditis relapse was low and the mortality rate was similar to that of patients without a history of infection.

This aim of this study was to evaluate the safety and the mid-term outcomes of TAVR in a setting of aortic valve infective endocarditis with residual lesion despite antibiotic treatment.

These patients are usually rejected by surgeons and TAVR is not a recommended option for them either.

Researchers retrospectively analyzed 46 patients from 10 sites, who were matched according to sex, EuroSCORE, kidney function, ventricular function, and prosthesis type (among others) so as to compare them with a cohort that was identical except for a history of endocarditis.


Read also: Ticagrelor to Improve Venous Graft Patency.


Compared with the general population who underwent TAVR, patients with a history of endocarditis experienced more frequently lesions in other valves and a much higher surgical risk. A previous aortic valve bioprosthesis was also much more frequent (50% vs. 7.5%; p < 0.001).

The mortality rates at 30 days and at one year were 5.6% and 11.1%, respectively. These figures were comparable with those of the control cohort.

III/IV aortic regurgitation was significantly higher in patients with a history of endocarditis (27.9% vs. 10%; p = 0.08), and this was independently associated with higher mortality. There was only one case of endocarditis relapse, but 18% of patients developed sepsis and 43% of patients were re-admitted over the year due to heart failure.

Conclusion

TAVR is a therapeutic alternative for the treatment of residual valvular lesions after endocarditis. At one year, the risk of endocarditis relapse was low and mortality rates were comparable to those for an equal-risk population without a history of endocarditis. Despite all of that, a fourth of these patients developed severe aortic regurgitation and half of them required re-admission.

Original Title: Transcatheter Aortic Valve Replacement for Residual Lesion of the Aortic Valve Following “Healed” Infective Endocarditis.

Reference: Sandra Santos-Martínez et al. J Am Coll Cardiol Intv 2020;13:1983–96. https://doi.org/10.1016/j.jcin.2020.05.033.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...